Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Elan Frova Migraine Launch To Follow Finalized Co-Marketing Agreement

  • News

Executive Summary

Elan's Frova acute migraine therapy launch awaits finalization of a co-marketing agreement, which is expected to take place by year-end

You may also be interested in...



Pfizer Relpax To Launch In First Quarter At Maximum Dose Of 40 Mg

Pfizer's Relpax migraine treatment will be launched during the first quarter at a maximum dose of 40 mg

Pfizer Relpax To Launch In First Quarter At Maximum Dose Of 40 Mg

Pfizer's Relpax migraine treatment will be launched during the first quarter at a maximum dose of 40 mg

UCB to comarket Elan Frova

UCB will contribute 475 primary care sales reps to comarket Elan migraine therapy Frova (frovatriptan) under agreement announced March 28. Companies plan for second quarter 2002 launch. Neurologists will be detailed with Elan and UCB combined sales force of 265 reps under seven-year agreement. Frova was approved Nov. 8 (1"The Pink Sheet" Nov. 12, 2001, p. 35)...

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS038817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By